- Home
- AHT vs BOLD Comparison
AHT vs BOLD Comparison
Compare AHT & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHT
- BOLD
- Stock Information
- Founded
- AHT 2003
- BOLD 2018
- Country
- AHT United States
- BOLD United States
- Employees
- AHT N/A
- BOLD 64
- Industry
- AHT Real Estate Investment Trusts
- BOLD
- Sector
- AHT Real Estate
- BOLD
- Exchange
- AHT Nasdaq
- BOLD Nasdaq
- Market Cap
- AHT 35.3M
- BOLD 24.4M
- IPO Year
- AHT 2003
- BOLD 2024
- Fundamental
- Price
- AHT $7.09
- BOLD $1.17
- Analyst Decision
- AHT
- BOLD Buy
- Analyst Count
- AHT 0
- BOLD 3
- Target Price
- AHT N/A
- BOLD $4.00
- AVG Volume (30 Days)
- AHT 48.8K
- BOLD 283.9K
- Earning Date
- AHT 07-30-2025
- BOLD 08-11-2025
- Dividend Yield
- AHT N/A
- BOLD N/A
- EPS Growth
- AHT N/A
- BOLD N/A
- EPS
- AHT N/A
- BOLD N/A
- Revenue
- AHT $1,143,655,000.00
- BOLD N/A
- Revenue This Year
- AHT N/A
- BOLD N/A
- Revenue Next Year
- AHT N/A
- BOLD N/A
- P/E Ratio
- AHT N/A
- BOLD N/A
- Revenue Growth
- AHT N/A
- BOLD N/A
- 52 Week Low
- AHT $5.20
- BOLD $1.00
- 52 Week High
- AHT $11.99
- BOLD $4.72
- Technical
- Relative Strength Index (RSI)
- AHT 70.01
- BOLD N/A
- Support Level
- AHT $6.09
- BOLD N/A
- Resistance Level
- AHT $7.55
- BOLD N/A
- Average True Range (ATR)
- AHT 0.47
- BOLD 0.00
- MACD
- AHT 0.15
- BOLD 0.00
- Stochastic Oscillator
- AHT 81.15
- BOLD 0.00
About AHT Ashford Hospitality Trust Inc
Ashford Hospitality Trust Inc. is a real estate investment trust that invests in full-service upscale and upper-upscale hotel properties in the U.S. The company owns and operates its assets through its operating partnership, Ashford Hospitality Limited Partnership. All of its hotels are located across the U.S. and operate under the Marriott, Hilton, Hyatt, Crowne Plaza, and Sheraton brands. Ashford's sole segment is Direct Hotel Investments, through which it owns hotels by acquisition or development. Ashford also provides real estate investment services, such as mezzanine financing, first mortgage financing, and sales-leaseback transactions. Its revenue streams include Room revenue, Food and beverage revenue, and Other revenue. Room revenue accounts for the majority of total revenue.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.